MedTrace Logo

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

NCT07093606 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-07-30

No results posted yet for this study

Summary

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Conditions

  • ITP - Immune Thrombocytopenia

Interventions

DRUG

Eltrombopag

ITP patients will receive Eltrombopag and evulate occurance of liver disordres .

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-14
Primary Completion
2026-01-20
Completion
2026-01-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07093606 on ClinicalTrials.gov